secwatch.observer — SEC 8-K summary
======================================

Issuer:     PHIBRO ANIMAL HEALTH CORP (PAHC)
CIK:        0001069899
Form:       8-K
Filed at:   2024-05-08T23:59:59+00:00
Accession:  0001558370-24-007371
Event type: earnings
Sentiment:  neutral
Materiality: 0.90
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Phibro Animal Health Reports Q3 FY2024 Results; Updates Guidance, Plans Zoetis Acquisition
--------------------------------------------------------------------------------

- Net sales for Q3 ended March 31, 2024 were $263.2M, up 7% YoY; Animal Health segment grew 10%.
- Adjusted EBITDA increased 9% to $29.7M; adjusted diluted EPS rose to $0.31 from $0.29.
- Affirmed FY2024 net sales guidance of $980M-$1.02B and Adjusted EBITDA of $106M-$112M.
- Signed agreement to acquire Zoetis' Medicated Feed Additive portfolio to enhance product offerings.
- Vaccine sales surged 26% and MFA and other sales increased 16% in the quarter.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1069899/000155837024007371/0001558370-24-007371-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1069899/000155837024007371/pahc-20240508x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-007371

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer